Breakthrough treatment boosts survival after severe blood loss

A team of researchers has made a significant breakthrough that could save countless lives in emergencies involving severe blood loss. Their new treatment involves activating a protein called PKC-ε soon after intense bleeding occurs. In their studies, this approach tripled survival rates, increasing them from 25% to an impressive 73%. Additionally, the treatment helped maintain healthy organ function by boosting cellular energy levels, offering hope for improved outcomes in emergency trauma care.

Researchers at the Hebrew University of Jerusalem and the IDF Medical Corps have discovered a promising new therapeutic approach to treating hemorrhagic shock, a life-threatening condition caused by severe blood loss that remains the leading cause of preventable death in trauma cases globally. The study, led by Dr. Ariel Furer and Dr. Maya Simchoni, from the Institute for Research in Military Medicine a joint project between Hebrew University-Hadassah Medical School and the Israel Defense Forces (IDF) Medical Corps demonstrates that activating Protein Kinase C epsilon (PKC-ε) significantly improves early survival rates and physiological stability following severe hemorrhage.

In a carefully controlled experiment using a porcine model, researchers induced hemorrhagic shock by withdrawing 35% of the animals' total blood volume. Animals treated with a PKC-ε activator peptide just five minutes after the onset of bleeding showed dramatically improved survival—73% of treated subjects survived compared to only 25% of those left untreated. Additionally, treated animals maintained significantly better cardiovascular stability, including blood pressure, heart rate, and cardiac output, all critical indicators of effective response during severe trauma.

Moreover, detailed analysis of mitochondrial activity revealed enhanced function within the heart tissues of animals receiving the PKC-ε activator. As mitochondria are vital cellular energy producers, these findings suggest that activating PKC-ε helps maintain organ energy levels under stress, potentially protecting tissues against further damage associated with severe blood loss.

The implications of this study are far-reaching. Current therapeutic strategies for severe hemorrhagic shock often involve fluid resuscitation, which can unintentionally exacerbate tissue damage by triggering ischemic-reperfusion injury. This new approach—administering a PKC-ε activator peptide—has the potential to significantly minimize these detrimental effects, thereby improving survival chances and reducing complications associated with severe trauma.

Dr. Ariel Furer commented on the broader implications: "Massive hemorrhage remains one of the most critical challenges faced in emergency medicine, particularly in battlefield and civilian trauma scenarios. Our findings suggest that activating PKC-ε can be a highly effective therapeutic approach, potentially transforming trauma care by providing frontline medical responders with a powerful tool to improve patient outcomes."

Published in the prestigious journal Scientific Reports, this study marks a critical step forward in trauma medicine. However, Dr. Furer notes that further clinical research is necessary before this treatment can be widely adopted in clinical settings.

"Our findings open new avenues for targeted therapeutic strategies that can be administered by first responders in emergency settings, potentially saving countless lives worldwide," concluded Dr. Furer. "Future clinical trials will be essential to validate these promising results and to move towards practical implementation."